Oncology Pharma (ID)【ONPH】銘柄情報

Oncology Pharma Inc (ID) (ONPH) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.0502

( -28.29% )

買値

0.0501

売値

0.07

出来高

23,540

0.0502 日の範囲 0.07

0.000001 52 週間の範囲 0.364

時価総額

1.941M

前日終値

0.07

始値

0.0698

時刻

251

0.0502

最終取引時間

財務取引量

US$ 1,449

VWAP

0.061571

平均取引量 (3 か月)

US$ 62,906

発行済株式数

38,663,215

配当利回り

PER

1 株当たり利益 (EPS)

歳入

10.21k

純利益

186.04k

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc... Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.oncology-pharma.com

本社

San Francisco, United States

設立

1993

Oncology Pharma Inc (ID) is listed in the Healthcare sector of the その他OTC with ticker ONPH. The last closing price for Oncology Pharma (ID) was US$0.07. Over the last year, Oncology Pharma (ID) shares have traded in a share price range of US$ 0.000001 to US$ 0.364.

Oncology Pharma (ID) currently has 38,663,215 shares in issue. The market capitalisation of Oncology Pharma (ID) is US$1.94 million.

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion...

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery...

Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development

Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for...

Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development

Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development ...

Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer

Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer San Francisco, CA -- April 13, 2022...

Oncology Pharma Reports on Progress with Ribera Solutions

SAN FRANCISCO, CA -- March 2, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company") is...

Oncology Pharma Releases Further Feasibility Studies, Data and Capacities

SAN FRANCISCO, CA -- February 23, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The Company...

Oncology Pharma Expands on Feasibility Studies and Data

SAN FRANCISCO, CA -- February 17, 2022 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc...

Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine

San Francisco, CA -- February 14, 2022 -- InvestorsHub NewsWire -- Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen...

Oncology Pharma Gives Update on Technology, Formulation and Data Creation

SAN FRANCISCO, CA – February 8, 2022 – InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0198	-28.2857142857	0.07	0.07	0.05	31833	0.06389133	CS
4	0.0017	3.50515463918	0.0485	0.11	0.0485	33594	0.06967565	CS
12	-0.0498	-49.8	0.1	0.15	0.03	36177	0.07681213	CS
26	0.0452	904	0.005	0.364	0.004	37642	0.06557964	CS
52	0.0501	50100	0.0001	0.364	1.0E-6	23698	0.05735937	CS
156	-0.3498	-87.45	0.4	0.43	1.0E-6	16099	0.09087444	CS
260	-30.6748	-99.8366151343	30.725	37.76	1.0E-6	71329	7.52292352	CS